Overview

Clinical Study of Irinotecan Hydrochloride Liposome Combined With Capecitabine for Second-line Treatment in Patients With Advanced or Metastatic Biliary Tract Carcinoma

Status:
NOT_YET_RECRUITING

Trial end date:
2025-12-31

Target enrollment:

Participant gender:

Summary

To evaluate the efficacy and safety of irinotecan hydrochloride liposome injection combined with Capecitabine for second-line treatment in Patients With advanced or metastatic biliary tract carcinoma.

Phase:

PHASE2

Details

Lead Sponsor:

Ba Yi

Collaborator:

CSPC Ouyi Pharmaceutical Co., Ltd.

Treatments:

Capecitabine